These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28951410)

  • 1. Cost-effectiveness of milk powder fortified with potassium to decrease blood pressure and prevent cardiovascular events among the adult population in China: a Markov model.
    Dainelli L; Xu T; Li M; Zimmermann D; Fang H; Wu Y; Detzel P
    BMJ Open; 2017 Sep; 7(9):e017136. PubMed ID: 28951410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Milk Powder Fortified with Potassium and Phytosterols to Decrease the Risk of Cardiovascular Events among the Adult Population in Malaysia: A Cost-Effectiveness Analysis.
    Gandola AE; Dainelli L; Zimmermann D; Dahlui M; Detzel P
    Nutrients; 2019 May; 11(6):. PubMed ID: 31151244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health impact and economic evaluation of vitamin D-fortified dairy products for fracture prevention in France.
    Hiligsmann M; Burlet N; Fardellone P; Al-Daghri N; Reginster JY
    Osteoporos Int; 2017 Mar; 28(3):833-840. PubMed ID: 27757506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
    Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
    PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation and Prediction of Avoidable Health Care Costs of Cardiovascular Diseases and Type 2 Diabetes Through Adequate Dairy Food Consumption: A Systematic Review and Micro Simulation Modeling Study.
    Javanbakht M; Jamshidi AR; Baradaran HR; Mohammadi Z; Mashayekhi A; Shokraneh F; Rezai Hamami M; Yazdani Bakhsh R; Shabaninejad H; Delavari S; Tehrani A
    Arch Iran Med; 2018 May; 21(5):213-222. PubMed ID: 29738265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
    Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
    Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness of different screening strategies for primary prevention of cardiovascular diseases in a rural northern Chinese population].
    Si YQ; Tang X; Zhang DD; He L; Cao Y; Wang JW; Li N; Liu JJ; Gao P; Hu YH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 50(3):443-449. PubMed ID: 29930411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
    Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
    Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
    Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
    BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and cost-effectiveness of a school-based education program to reduce salt intake in children and their families in China.
    Li X; Jan S; Yan LL; Hayes A; Chu Y; Wang H; Feng X; Niu W; He FJ; Ma J; Han Y; MacGregor GA; Wu Y
    PLoS One; 2017; 12(9):e0183033. PubMed ID: 28902880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <120 mmHg in Hypertensive Patients Without Diabetes Mellitus.
    Almalki ZS; Iqbal MS; Alablan FM; Alenazi RK; Tasha AR; Daghar MF; Aldossary NM
    Value Health Reg Issues; 2020 May; 21():157-163. PubMed ID: 31978689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures.
    Ethgen O; Hiligsmann M; Burlet N; Reginster JY
    Osteoporos Int; 2016 Jan; 27(1):301-8. PubMed ID: 26395885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
    Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
    J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of intensive hypertension control in China.
    Xie X; He T; Kang J; Siscovick DS; Li Y; Pagán JA
    Prev Med; 2018 Jun; 111():110-114. PubMed ID: 29525577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
    Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
    Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model.
    Zomer E; Owen A; Magliano DJ; Liew D; Reid CM
    BMJ; 2012 May; 344():e3657. PubMed ID: 22653982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of initiation of antihypertensive therapy strategies for primary prevention of cardiovascular diseases in Chinese population: A decision-analytic Markov modelling study].
    Zhou T; Liu Q; Zhang M; Liu X; Kang J; Shen P; Lin H; Tang X; Gao P
    Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 56(3):441-447. PubMed ID: 38864129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of the Haemophilus influenzae type b vaccine for infants in mainland China.
    Ning G; Yin Z; Li Y; Wang H; Yang W
    Hum Vaccin Immunother; 2018 Jan; 14(1):36-44. PubMed ID: 29049002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.